CLINICAL STUDY

The prevalence of thyroid disorders during early pregnancy in China: the benefits of universal screening in the first trimester of pregnancy

Weiwei Wang^{1,2}, Weiping Teng², Zhongyan Shan^{1,2}, Sen Wang², Jianxin Li², Lin Zhu², Jin Zhou², Jinyuan Mao², Xiaohui Yu², Jia Li², Yanyan Chen², Haibo Xue², Chenling Fan², Hong Wang², Hongmei Zhang², Chenyang Li³, Weiwei Zhou⁴, Bo Gao⁵, Tao Shang⁶, Jiaren Zhou⁶, Bin Ding³, Ying Ma⁷, Ying Wu⁸, Hui Xu⁹ and Wei Liu¹⁰

¹Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, People's Republic of China, 110001,

²The Endocrine Institute of China Medical University, The Liaoning Provincial Key Laboratory of Endocrine diseases, Shenyang, People's Republic of China, 110001, ³Shenyang No. 5 People's Hospital, Shenyang, People's Republic of China, 110023, ⁴Women and Infants Hospital of Shenyang, Shenyang, People's Republic of China, 110014, ⁵Shenyang No. 4 People's Hospital, Shenyang, People's Republic of China, 110031, ⁶Second Affiliated Hospital, China Medical University, Shenyang, People's Republic of China, 110004, ⁷Shenzhou Hospital of Shenyang, Shenyang, People's Republic of China, 110002, ⁸Shenyang No. 9 People's Hospital, Shenyang, People's Republic of China, 110024, ⁹Women and Infants Hospital of Heping District of Shenyang, Shenyang, People's Republic of China, 110005 and ¹⁰Shenyang No. 8 People's Hospital, Shenyang, People's Republic of China, 110024

(Correspondence should be addressed to Z Shan; Email: shanzhongyan@medmail.com.cn or to W Teng; Email: twpendocrine@yahoo.com.cn)

Abstract

Context: Maternal thyroid disorders during early pregnancy can influence pregnancy outcome and fetal development. The recent Endocrine Society Clinical Practice Guideline recommends a case-finding approach in which pregnant women who are at high risk for developing thyroid disease are tested.

Objective: The purpose of this study was to use the first trimester-specific reference intervals of thyroid-related hormones to explore the prevalence of thyroid dysfunction during early pregnancy and to analyze effectiveness of different screening strategies.

Design: A multicenter cohort study.

Method: A total of 2899 pregnant women were enrolled in this study during their first trimester of gestation. Levels of TSH, free thyroxine, free triiodothyronine, and thyroid peroxidase antibodies (TPOAb) were measured and thyroid disorders of pregnant women were diagnosed based on the first trimester-specific reference intervals.

Results: The prevalence of hypothyroidism was significantly higher in the high-risk group than in the non-high-risk group (10.9 vs 7.0%, $\chi^2 = 7.1$, $P = 0.008$). The prevalence of hyperthyroidism was not significantly different between the high-risk group and the non-high-risk group (2.7 vs 1.6%, $\chi^2 = 2.27$, $P = 0.13$). Elevated levels of TPOAb and a personal history of thyroid disease increased the risk of thyroid dysfunction.

Conclusions: A case-finding strategy for screening thyroid function in the high-risk group would miss about 81.6% pregnant women with hypothyroidism and 80.4% pregnant women with hyperthyroidism.

European Journal of Endocrinology 164 263–268

Introduction

Development of maternal thyroid disorders during early pregnancy can influence the pregnancy outcome and fetal development. Thyroid dysfunction can lead to premature birth, pregnancy-induced hypertension, increased fetal mortality, and low infant birth weight (1–4). Maternal hypothyroidism and hypothyroxinemia in the first trimester of pregnancy may be harmful to fetal brain development and lead to mental retardation (5, 6). In view of the potential adverse outcomes associated with maternal thyroid disorders and the

obvious benefits of treatment, some expert panels have suggested routine thyroid function screening in all pregnant women (7, 8). However, the Endocrine Society Clinical Practice Guideline (9) recommends a case-finding approach where only women at high-risk for thyroid disorders are tested; these women include those who have a personal or family history of thyroid disease, a personal history of type I diabetes, or other autoimmune disorders, clinical signs suggestive of thyroid disorders, goiter, thyroid antibodies, history of previous therapeutic head or neck irradiation or a history of miscarriage, preterm delivery, or infertility.

The aim of this study is to use the first trimester-specific reference intervals of thyroid-related hormones to determine the prevalence of thyroid dysfunction during early pregnancy and to evaluate efficiency of the case-finding strategy versus the universal screening strategy.

Materials and methods

Subjects

Women were recruited from routine antenatal clinics in ten hospitals from May 2005 through June 2008 in Shenyang, China. Eligibility criteria included pregnant women within the first 12 weeks of gestation and no history of living in endemic goiter areas. A total of 2899 pregnant women living in iodine-adequate areas in their first trimester of pregnancy participated. The medical ethics committee of the First Affiliated Hospital of China Medical University approved this study and all participating women gave informed written consent. Duration of gestation was calculated based on the dates of their last menstrual period and confirmed by ultrasonography. All participants specifically answered a questionnaire about reproductive histories (miscarriages, preterm deliveries, and infertility), personal and family history of thyroid disorders (including first- and second-degree relatives), personal history of type I diabetes or other autoimmune diseases, and history of therapeutic head or neck irradiation by the obstetrician of the ten hospitals. Based on Endocrine Society Clinical Practice Guidelines, women with a personal or family history of thyroid disease, a personal history of type I diabetes or other autoimmune disorders, clinical signs suggestive of thyroid disorders, goiter, thyroid antibodies, a history of previous therapeutic head or neck irradiation, a history of miscarriage, preterm delivery, and infertility were identified as at high risk for thyroid disease during pregnancy (9).

Methods of sampling and laboratory testing

Blood samples were obtained from each participant in the morning after an overnight fast. All sera obtained were immediately analyzed for TSH, free thyroxine (FT₄), free triiodothyronine (FT₃), and thyroid peroxidase antibody (TPOAb) concentrations, using a chemiluminescence immunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA). The functional sensitivity of the TSH assay was 0.02 mIU/l. The intra-assay coefficients of variation (CV) of serum TSH, FT₄, FT₃, TPOAb were 1.57–4.12, 2.24–6.33, 0.57–4.31, and 2.42–5.63% respectively. The inter-assay CV values were 1.26–5.76, 4.53–8.23, 3.50–5.19, and 5.23–8.16% respectively. Urinary iodine excretion was measured by the colorimetric ceric ion arsenious acid ash method, based on the Sandell–Kolthoff reaction. The intra- and inter-assay CV values were <7%.

Trimester-specific reference intervals for TSH, FT₃, and FT₄ and diagnostic criteria

The first trimester-specific reference intervals used to diagnose thyroid dysfunctions were based on those determined previously (10). The first trimester-specific reference ranges for TSH, FT₄, and FT₃ were 0.13–3.93 mIU/l, 12.00–23.34 pM, and 3.46–7.70 pM respectively. Overt hypothyroidism, subclinical hypothyroidism, and hypothyroxinemia were defined by the first trimester-specific reference intervals for TSH, FT₃, and FT₄ as described previously (10). Overt hyperthyroidism and subclinical hyperthyroidism were identified as decreased TSH levels with increased FT₃ or FT₄ and with a normal range of FT₃ or FT₄ respectively. A TPOAb concentration ≥ 50 IU/ml was considered abnormal.

Women who were found to have thyroid dysfunction or euthyroid women with TPOAb positive had thyroid function tests at least once during the second and third trimesters. Women with subclinical hypothyroidism were recommended to receive L-T₄ treatment and the drug dosage was adjusted according to their serum TSH level. Women with clinical hypothyroidism were offered treatment. Treatment of hyperthyroidism women was based on the endocrinologist's clinical judgment and, if necessary, antithyroid drug was administered.

Statistical analysis

Data analysis was performed using SPSS software (version 14.5., SPSS, Inc., Cary, NJ, USA). Statistical comparisons were analyzed with the χ^2 test. A *P* value ≤ 0.05 was considered to be statistically significant. Based on the results of the χ^2 test, statistically significant variables were assessed by multivariate logistic regression analysis.

Results

Characteristics of pregnant women

The average age of the 2899 women enrolled in the study was 27.61 ± 3.55 years old and the median duration of pregnancy at initial analysis was 6 weeks (4–12 weeks). Median urinary iodine of these pregnant women was 177.15 µg/l. Fifty-two women (1.8%) had personal history of thyroid disorders, which included 21 hypothyroidism (overt or subclinical), 11 hyperthyroidism (overt or subclinical), 11 goiter/thyroid nodule, and 9 other thyroid disorders; 179 women (6.0%) had family history of thyroid disorders. Three women (0.1%) had history of other autoimmune diseases; 147 women (5.0%) had history of miscarriage. Three women (0.1%) had history of preterm delivery and five women (0.2%) had history of infertility treatment. None had history of head or neck irradiation. Using the Endocrine Society Clinical Practice guidelines (9), we classified 367 (12.7%) women, who had a personal or family

Table 1 Demographic characteristics of pregnant women.

Demographic characteristics (n=2899)	
Mean maternal age (years) ($\bar{x} \pm s$)	27.61 $\pm$ 3.55
Median (range) gestational age at screening (weeks)	6 (4–12)
Median urinary iodine ($\mu\text{g/l}$)	177.15
Number of previous pregnancies, n (%)	
None	1492 (51.5%)
One	797 (27.5%)
Two	409 (14.1%)
Three or more	196 (6.7%)
History of fertility treatment, n (%)	5 (0.17%)
History of miscarriages, n (%)	147 (5.0%)
History of preterm delivery, n (%)	3 (0.1%)
History of smoking, n (%)	41 (1.4%)
Personal history of thyroid disease, n (%)	52 (1.8%)
Hyperthyroidism	21 (0.7%)
Hypothyroidism	11 (0.4%)
Goiter/nodule	11 (0.4%)
Other thyroid disease	9 (0.3%)
History of head or neck irradiation, n (%)	0 (0.0%)
Family history of thyroid disease, n (%)	179 (6.2%)
Type 1 diabetes/autoimmune disease ^a , n (%)	3 (0.1%)

^aIncluding rheumatoid arthritis (n=3).

history of thyroid disease, a personal history of type 1 diabetes or other autoimmune disorders, a history of miscarriage, preterm delivery and infertility, a history of head or neck irradiation, as high risk (9). Demographic characteristics of participants are shown in Table 1. There were no significant differences in maternal age, ethnicity, smoking habits, or number of previous pregnancies between the women in the high-risk group and those in the non-high-risk group (data not shown).

Prevalence of thyroid dysfunction in the first trimester of pregnancy and relative risk analysis

TSH, FT₄, FT₃, and TPOAb levels were measured in all 2899 pregnant women. Of the 2899 women in the study, 294 women had thyroid dysfunction.

The prevalence of thyroid dysfunction was 10.2%. The prevalences of hyperthyroidism, hypothyroidism, and hypothyroxinemia were 1.8, 7.5, and 0.9% respectively (Table 2). TPOAb was positive in 279 (9.6%) of the 2899 women. The number of euthyroid women with antibodies was 196 (6.8%). The prevalence of thyroid dysfunction in the high-risk group was significantly higher than in non-high-risk group (15.0 vs 9.4%, $P=0.001$, $\chi^2=10.8$). The prevalence of thyroid dysfunction in pregnant women with personal history of thyroid diseases (30.8 vs 9.8%, $P=0.000$), abnormal TPOAb levels (29.7 vs 8.1%, $P=0.000$), and personal history of other autoimmune disorders (66.7 vs 10.1%, $P=0.018$) was significantly higher than in pregnant women without the risk factors. A logistic multiple regression showed that personal history of thyroid diseases (odds ratio (OR)=2.3, $P=0.016$) and positive TPOAb (OR=4.6, $P=0.000$) were the risk factors for the increase in thyroid dysfunction.

Prevalence of hypothyroidism, hyperthyroidism, and hypothyroxemia in the first trimester of pregnancy and relative risks analysis

Two hundred and seventeen women (7.5%) had elevated TSH levels. Eight of them were diagnosed with overt hypothyroidism. Of the eight women with raised TSH and low FT₄, seven had TPOAbs. The prevalence of elevated TSH was higher in the high-risk group than in the non-high-risk group (10.9 vs 7.0%, $\chi^2=7.1$, $P=0.008$). Personal history of thyroid disease (n=51) and the prevalence of hypothyroidism in TPOAb-positive pregnant women (n=279) were significantly higher than those in TPOAb-negative pregnant women (25.8 vs 5.5%, $P=0.000$) and non-personal history of thyroid disease pregnant women (23.1 vs 7.2%, $P<0.001$). It was noteworthy that 177 of 217 women with elevated TSH (81.6%) were in the non-high-risk group.

Fifty-one women (1.8%) with low TSH levels were diagnosed with overt or subclinical hyperthyroidism.

Table 2 The prevalence of thyroid disorders during early pregnancy based on various characteristics. Data are expressed as n (%).

Sample characteristics	n	Low TSH			Elevated TSH			Normal TSH
		High FT ₄	Normal FT ₄	Total	Low FT ₄	Normal FT ₄	Total	Low FT ₄
All women	2899	28 (1.0)	23 (0.8)	51 (1.8)	8 (0.3)	209 (7.2)	217 (7.5)	26 (0.9)
High-risk group	367	7 (1.9)	3 (0.8)	10 (2.7)	2 (0.5)	38 (10.4)	40 (10.9)	5 (0.9)
Non-high-risk group	2532	21 (0.8)	20 (0.8)	41 (1.6)	6 (0.2)	171 (6.8)	177 (7.0)	21 (0.9)
TPOAb positive	279	7 (2.5)	4 (1.5)	11 (4.0)	7 (2.5)	65 (23.3)	72 (25.8)	0
History of thyroid disorder	52	4 (7.7)	0	4 (7.7)	2 (3.9)	10 (19.2)	12 (23.1)	0
Family history of thyroid disease	179	3 (1.7)	3 (1.7)	6 (3.5)	0	16 (9.2)	16 (9.2)	2 (1.1)
History of other autoimmune diseases	3	0	0	0	0	1 (33.3)	1 (33.3)	1 (33.3)
History of miscarriages	147	1 (0.7)	0	1 (0.7)	0	14 (9.5)	14 (9.5)	2 (1.4)
History of preterm delivery	3	0	0	0	0	0	0	0
History of fertility treatment	5	1 (20)	0	1 (20)	0	0	0	0

Figure 1 Comparison of the prevalence of thyroid disorders in the high-risk group and the non-high-risk group.

There was no difference in the prevalence of hyperthyroidism between the high-risk group and the non-high-risk group (2.7 vs 1.6%, $\chi^2=2.27$, $P=0.13$). Personal history of thyroid disease ($n=51$) and the prevalence of hyperthyroidism in TPOAb-positive pregnant women ($n=279$) were significantly higher than those in TPOAb-negative pregnant women (4.0 vs 1.5%, $P=0.007$) and non-personal history of thyroid disease pregnant women (7.7 vs 1.7%, $P=0.006$). It was noteworthy that only 10 of 51 (19.6%) women with hyperthyroidism belonged to the high-risk group; 41 (80.4%) women with hyperthyroidism were in the non-high-risk group.

There was no difference in the prevalence of hypothyroxemia between the high-risk group and the non-high-risk group (0.9 vs 0.9%, $\chi^2=0.008$, $P=0.928$). **Figure 1** compares the prevalence of thyroid disorders in the high-risk group and the non-high-risk group and **Fig. 2** presents the rates of missed diagnoses if screening were to be performed only in the high-risk population.

A logistic multiple regression was used for risk factor analysis. It showed that positive TPOAb was a risk factor (OR=5.8, $P=0.000$) for the increase in hypothyroidism and the presence of TPOAb (OR=2.3, $P=0.022$) and personal history of thyroid diseases (OR=3.6, $P=0.025$) increase the risk of hyperthyroidism (**Table 3**).

Discussion

Maternal overt hypothyroidism, subclinical hypothyroidism, and hypothyroxinemia are associated with adverse outcomes in pregnancy, including miscarriage, pregnancy-induced hypertension, preterm delivery, placental abruption, and impaired neuropsychological development of children (1–6). Haddow *et al.* (5) and Pop *et al.* (6) reported that maternal hypothyroidism and hypothyroxinemia occurring in the first half of pregnancy may be harmful to the embryo-fetal brain development and lead to intellectual retardation in the offspring. Our group also found that maternal

subclinical hypothyroidism, hypothyroxinemia, and euthyroidism with elevated TPOAb titers were all statistically significant predictors of lower motor and intellectual development at 25–30 months (11). In Haddow's report, the IQ scores of children whose mothers with hypothyroidism were treated during pregnancy were similar to those of the control children of mothers with normal thyroid function during pregnancy (5). Berbel *et al.* (12) reported that a delay of 6–10 weeks in iodine supplementation of hypothyroxinemic mothers at the beginning of gestation in an area of mild iodine deficiency increases the risk of neurobehavioral performance delay in their offsprings.

Maternal thyroid function is of great importance for the fetus during the first trimester of pregnancy. Stricker *et al.* (13) reported that 3.6% of patients with elevated TSH would be missed and 3.7% of patients with low TSH level would be misdiagnosed as having a lower TSH level by using the non-pregnant reference intervals to diagnose thyroid diseases. Vaidya *et al.* (14) concluded that the prevalence of hypothyroxemia increased 3.7% when the first trimester-specific reference ranges were used rather than general population reference intervals. Our group used two different series of reference intervals to calculate the prevalence of thyroid hormone deficiency and also found that 2% patients with subclinical hypothyroidism would be misclassified if general population reference intervals were used (10). These results indicate that the first trimester-specific reference ranges must be used to evaluate thyroid function in pregnancy.

In this study, we evaluated the prevalence of thyroid dysfunction by screening 2899 pregnant women using the first trimester-specific reference intervals from our previous work (10). The results showed that high-risk women, classified based on Endocrine Society Clinical Practice Guidelines (9), had more than a 1.5-fold increased risk of hypothyroidism (subclinical or overt) and a 1.7-fold increased risk of hyperthyroidism (subclinical or overt) during early pregnancy than did women in the non-high-risk group. However, screening for thyroid diseases only in the high-risk pregnant women, as the guidelines recommend, would have meant that about 81.6% women with hypothyroidism (2.7% with overt hypothyroidism and 78.8% with

Figure 2 The rates of missed diagnoses if screening were to be performed only in the high-risk population.

Table 3 Relative risks for hypothyroidism and hyperthyroidism at screening.

Risk factors	Hypothyroidism			Hyperthyroidism		
	OR	95% CI	P	OR	95% CI	P
TPOAb positive	5.8	4.2–8.1	0.000	2.3	1.1–4.7	0.022
Personal history of thyroid disorder	2.0	1.0–4.2	0.057	3.6	1.2–10.9	0.025
Family history of thyroid disorders	1.0	0.6–1.8	0.879	1.9	0.8–4.5	0.172
Personal history of other autoimmune disorders	3.5	0.3–44.6	0.342	0.0	0.0	0.999
History of miscarriage	1.2	0.7–2.2	0.584	0.2	0.3–1.8	0.169
History of preterm delivery	0.0	0.0	0.999	0.0	0.0	0.999
History of fertility treatment	0.0	0.0	0.999	17.0	1.9–155.2	0.012

subclinical hypothyroidism) and 80.4% women with hyperthyroidism (41.2% with overt hyperthyroidism and 39.2% with subclinical hyperthyroidism) would be missed. Our results were similar to those reported by Vaidya *et al.* (14), who concluded that targeted thyroid function testing of only high-risk pregnant women would miss nearly one third of women with overt/subclinical hypothyroidism during early pregnancy by using non-pregnant population reference intervals. A higher percentage of missed diagnoses occurred in this study than in the Vaidya study maybe because Vaidya defined euthyroidism in that study as a TSH <4.2, whereas this study defined euthyroidism as a TSH <3.93. Recently, another study (15) reached similar conclusions. In that study, pregnant women were randomized in the first trimester to either universal screening group or case-finding group. The study showed that the case-finding approach fails to detect the majority of pregnant women with thyroid dysfunction (15). The benefits and risks of universal testing or case-finding strategies in pregnant women are debated (16–19). As Brent (8) had previously pointed out that the potential adverse outcomes are so significant and the tools to diagnose and treat thyroid disease are easily accessible, that it is no longer acceptable for even one third of pregnant women to remain undiagnosed. Our results support performing universal screening early in pregnancy for thyroid disorders using the first trimester-specific reference intervals. In 2008, Dosiou *et al.* (20) reported that screening pregnant women for TSH concentrations in the first trimester of pregnancy was cost saving compared with no screening, and screening using anti-TPO antibodies was also economically favorable. The study of Thung used marginal cost per quality-adjusted life year as the main outcome measure and show that universal screening for subclinical hypothyroidism in pregnancy would be a cost-effective strategy (21). Regarding the main argument against universal screening has been the lack of clinical trial evidence showing that treatment for mild maternal hypothyroidism prevents neuropsychological deficit in children and other obstetric complications and also that more randomized trials are needed.

The most appropriate screening test for thyroid dysfunction in early pregnancy is still uncertain. Most

would advocate using TSH as the initial screening test, because TSH is a more sensitive marker of thyroid status than FT₄ and it reflects the physiologic log/linear relationship of TSH to FT₄ (22, 23). TPOAb measurement should also be considered due to the relationship with adverse pregnancy events, such as *post partum* thyroiditis, recurrent miscarriage, and *post partum* depression. In addition, 20–30% of women with *post partum* thyroiditis develop permanent hypothyroidism (24, 25). Negro *et al.* reported that treatment of euthyroid pregnant women who were positive for TPOAb with L-T₄ lowered the chance of miscarriage and premature delivery. Selenium supplementation during pregnancy and in the *post partum* period also reduces thyroid inflammatory activity and the incidence of *post partum* thyroid dysfunction and hypothyroidism (26, 27). Maternal hypothyroxinemia during pregnancy may affect neuropsychological development of offspring (6, 11, 12), which affected 0.9% of the cohort of this study with equal frequency in the high-risk and non-high-risk groups, and is identified only if serum TSH is measured. Therefore, we support using TSH, FT₄, and TPOAb as the initial screening test for thyroid dysfunction in early pregnancy.

In conclusion, our study confirms that a case-finding strategy for screening thyroid function would miss about 81.6% pregnant women with hypothyroidism and 80.4% pregnant women with hyperthyroidism.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The study was supported by the National Public Welfare Foundation, the Healthcare Special Project (grant numbers 200802008), and the Social Development Foundation in Liaoning Province (grant numbers 2007225010), all in China.

Acknowledgements

We are indebted to the residents of Shenyang who participated in this study and gratefully acknowledge the help of doctors from ten hospitals of Shenyang.

References

- Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, Faix JD & Klein RZ. Maternal thyroid deficiency and pregnancy complications: implications for population screening. *Journal of Medical Screening* 2000 **7** 127–130. (doi:10.1136/jms.7.3.127)
- Casey BM & Leveno KJ. Thyroid disease in pregnancy. *Obstetrics and Gynecology* 2006 **108** 1283–1292. (doi:10.1097/01.AOG.0000244103.91597.c5)
- Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd EW, Leveno KJ & Cunningham FG. Subclinical hypothyroidism and pregnancy outcomes. *Obstetrics and Gynecology* 2005 **105** 239–245. (doi:10.1097/01.AOG.0000152345.99421.22)
- Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A & Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. *Thyroid* 2002 **12** 63–66. (doi:10.1089/105072502753451986)
- Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD & Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *New England Journal of Medicine* 1999 **341** 549–555. (doi:10.1056/NEJM199908193410801)
- Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL & de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clinical Endocrinology* 2003 **59** 282–288. (doi:10.1046/j.1365-2265.2003.01822.x)
- Gharib H, Tuttle RM, Baskin J, Fish LH, Singer PA & McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. *Thyroid* 2005 **15** 24–28. (doi:10.1089/thy.2005.15.24)
- Brent GA. Diagnosing thyroid dysfunction in pregnant women: is case finding enough? *Journal of Clinical Endocrinology and Metabolism* 2007 **92** 39–41. (doi:10.1210/jc.2006-2461)
- Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinioer D, Mandel SJ & Stagnaro-Green A. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism* 2007 **92** (Suppl) S1–S47. (doi:10.1210/jc.2007-0141)
- Shan ZY, Chen YY & Teng WP. A study for maternal thyroid hormone deficiency during the first half of pregnancy in China. *European Journal of Clinical Investigation* 2009 **39** 37–42. (doi:10.1111/j.1365-2362.2008.02055.x)
- Li Y, Shan Z, Teng W, Yu X, Li Y, Fan C, Teng X, Guo R, Wang H, Li J, Chen Y, Wang W, Chawinga M, Zhang L, Yang L, Zhao Y & Hua T. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months. *Clinical Endocrinology* 2010 **72** 825–829. (doi:10.1111/j.1365-2265.2009.03743.x)
- Berbel P, Mestre JL, Santamaría A, Palazón I, Franco A, Graells M, González-Torga A & de Escobar GM. Delayed neurobehavioral development in children born to pregnant women with mild hypothyroxinemia during the first month of gestation: the importance of early iodine supplementation. *Thyroid* 2009 **19** 511–519. (doi:10.1089/thy.2008.0341)
- Stricker RT, Echenard M & Eberhart R. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. *European Journal of Endocrinology* 2007 **157** 509–514. (doi:10.1530/EJE-07-0249)
- Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S & Bilous R. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding. *Journal of Clinical Endocrinology and Metabolism* 2007 **92** 203–207. (doi:10.1210/jc.2006-1748)
- Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T & Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. *Journal of Clinical Endocrinology and Metabolism* 2010 **95** 1699–1707. (doi:10.1210/jc.2009-2009)
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician–gynecologists. Number 37, August 2002 (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. *Obstetrics and Gynecology* 2002 **100** 387–396. (doi:10.1016/S0029-7844(02)02196-8)
- Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NE, Colin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS & Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *Journal of the American Medical Association* 2004 **291** 228–238. (doi:10.1001/jama.291.2.228)
- Hollowell JG, LaFranchi S, Smallridge RC, Spong CY, Haddow JE & Boyle CA. Where do we go from here? Summary of working group discussions on thyroid function and gestational outcomes *Thyroid* 2005 **15** 72–76. (doi:10.1089/thy.2005.15.72)
- American Thyroid Association. Consensus Statement #2: American Thyroid Association statement on early maternal thyroidal insufficiency: recognition, clinical management and research directions. *Thyroid* 2005 **15** 77–79. (doi:10.1089/thy.2005.15.77)
- Dosiou C, Sanders GD, Araki SS & Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. *European Journal of Endocrinology* 2008 **158** 841–851. (doi:10.1530/EJE-07-0882)
- Thung SF, Funai EF & Grobman WA. The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. *American Journal of Obstetrics and Gynecology* 2009 **200** 267.e1–267.e7. (doi:10.1016/j.ajog.2008.10.035)
- Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, Leveno KJ & Cunningham FG. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. *Obstetrics and Gynecology* 2005 **106** 753–757. (doi:10.1097/01.AOG.0000175836.41390.73)
- Mandel SJ, Spencer CA & Hollowell JG. Are detection and treatment of thyroid insufficiency in pregnancy feasible? *Thyroid* 2005 **15** 44–53. (doi:10.1089/thy.2005.15.44)
- Premawardhana LD, Parkes AB & Ammari F. Postpartum thyroiditis and long-term thyroid status: prognostic influence of thyroid peroxidase antibodies and ultrasound echogenicity. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 71–75. (doi:10.1210/jc.85.1.71)
- Pop VJ, De Rooy HA & Vader HL. Postpartum thyroid dysfunction and depression in an unselected population. *New England Journal of Medicine* 1991 **324** 1815–1816. (doi:10.1056/NEJM199106203242516)
- Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D & Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. *Journal of Clinical Endocrinology and Metabolism* 2007 **92** 1263–1268. (doi:10.1210/jc.2006-1821)
- Negro R, Formoso G, Mangieri T, Pezzarossa A, Sazzi D & Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 2587–2591. (doi:10.1210/jc.2005-1603)

Received 26 October 2010

Accepted 8 November 2010